Inc> for six  mln dlrs in cash, a 13,550,000 dlr promissory note and warrants  to buy 200,000 PharmaControl common shares.
PharmaControl said it expects to make the payment due to  Revco from proceeds of a proposed offering of units consisting  of convertible subordinated debenturers and common stock  currently on file with the Securities and Exchange Commission.
Upon closing of the public offering, the company said, it  expects the secured institutional financing to increase to a  total of 12 mln dlrs.